For instance, analysis of certain biomarker expression such as PD‐L1 on cancer cells was used to identify patient susceptibility to PD‐1 blockade therapies.[38] In addition, the loss of immunogenic mutations or reduced expression of genes relevant to cancer immunotherapy under strong immune selective pressure can reshape the genetic landscape of cancers to limit sustained response to checkpoint inhibitors.[39] Either tumor‐intrinsic or microenvironmental factors that dynamically shape immune interactions can be potentially recaptured by advanced screening strategies. The gene discussed is CD274; the disease is cancer.